SOURCE: Benda Pharmaceutical, Inc.

August 15, 2007 12:00 ET

Benda Subsidiary Jiangling Benda Resumes Production

HUBEI PROVINCE, CHINA--(Marketwire - August 15, 2007) - Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, announced today that it has resumed production at its Jiangling Benda facility.

Jiangling Benda Reopened

The mayor of Jiangling County was in attendance when Benda's subsidiary, Jiangling Benda, reopened and began production of one of its primary products, Ribose, on Friday, August 10th. Jiangling Benda was temporarily closed while the plant underwent an upgrade to meet GMP certification standards. Jiangling Benda expects to receive its Good Manufacturing Practice (GMP) certification during the month of September; however, on August 10th, the plant began production of Ribose as it does not require GMP certification.

Jiangling Benda produces active pharmaceutical ingredients used in tablets, capsules and fluids. The plant has an annual production capacity of 800 tons of Ribose, the largest capacity production in the Hubei Province.

Benda Reaffirms Jiangling's 2007 Financial Projections

Mr. Wan, Benda CEO, reaffirmed that "Management fully expects Jiangling Benda to meet the plant's projected revenue of $10.7 million and net income of $1.9 million for the full year 2007."

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.BendaPharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward looking statements if they comply with the requirements of the Act.

Contact Information